行情

MDCO

MDCO

麦迪逊医药
NASDAQ

实时行情|Nasdaq Last Sale

51.98
+1.09
+2.14%
盘后: 51.98 0 0.00% 16:44 11/15 EST
开盘
52.05
昨收
50.89
最高
52.22
最低
49.16
成交量
212.10万
成交额
--
52周最高
58.48
52周最低
16.69
市值
41.44亿
市盈率(TTM)
-16.5964
分时
5日
1月
3月
1年
5年

分析师评级

13位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MDCO 新闻

  • The Medicines Company Announces ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing at AHA Scientific Sessions
  • Benzinga.4小时前
  • The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
  • Business Wire.9小时前
  • Edited Transcript of MDCO earnings conference call or presentation 30-Oct-19 12:30pm GMT
  • Thomson Reuters StreetEvents.2天前
  • Best-Performing Small-Cap Stocks YTD: November 2019
  • Seeking Alpha - Article.3天前

更多

所属板块

制药
+1.37%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

MDCO 简况

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.
展开

Webull提供The Medicines Company的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。